iiinova — where your digital self keeps evolving

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 03/10/2025

The EARLY study will track patients with incidental, asymptomatic IBD to uncover genetic, immune & clinical markers of disease in its preclinical phase. With 10-year follow-up, it aims to predict outcomes & guide early intervention strategies. journals.sagepub.com/doi/epdf/10....

021

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 03/10/2025

Survey of Moroccan gastroenterologists shows heavy workloads (50h+/week) linked to high rates of musculoskeletal (87%), digestive (71%), anxiety (24%), depression (46%), and burnout (72%). Younger doctors most affected, with worse work–life balance. journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 03/10/2025

US cohort shows vitamin D deficiency increases risk of cirrhosis HR 1.30, HCC HR 1.22, and mortality HR 1.14. Achieving sufficiency lowered death risk HR 0.93 but not cirrhosis. Lowest liver risk seen at 40–60 ng/mL, suggesting a U-shaped pattern. journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 03/10/2025

Review outlines strategies for 10–20 mm non-pedunculated colorectal polyps: CSP offers low AE risk, modified EMR boosts en bloc rates by 15–20%, while ESD is preferred for invasive/fibrotic cases. Emerging bipolar/low-power snares may cut thermal AEs. journals.sagepub.com/doi/epdf/10....

011

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 26/09/2025

Study (n=50) in unresectable #HCC: response to TACE was tied to peripheral T-cell profiles. Non-responders had more senescent/exhausted CD8+ T cells & fewer memory stem cells. Baseline CD8+ TSCM & TSenescence subsets may predict TACE efficacy & survival. journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 26/09/2025

Cross-sectional study (n=345) in China: 39.7% of ulcerative colitis pts reported disability (IBD-DI). Disability linked to higher disease activity, fatigue, depression & lower BMI. Independent risk factors: BMI, Mayo score, fatigue, depression. journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 26/09/2025

Retrospective study (n=65) of HER2+ advanced #GastricCancer treated with trastuzumab deruxtecan: ORR 36%, median OS 7.7 mo. Early tumor shrinkage was a strong predictor of longer PFS (HR 0.21) & OS (HR 0.23). T-DXd showed efficacy with manageable safety. journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 26/09/2025

Retrospective cohort in Vietnam: delayed ERCP for stone-induced acute cholangitis gave comparable outcomes to early ERCP, with similar mortality/readmission. Early ERCP shortened hospital stay, but dERCP offers a safe option in resource-limited settings journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 26/09/2025

Prospective study in #IBD: 91.8% accepted switch from originator adalimumab to biosimilars. Persistence 60.4% at 12 mo; remission maintained in 90.4%. Injection site pain was main discontinuation cause. Majority reported positive experience with switch journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 18/09/2025

Retrospective analysis of 1259 colorectal polyps (1025 pts) after EMR shows complete titanium clip closure reduces delayed postpolypectomy bleeding (#DPPB). Partial closure, male sex & larger polyps were significant risk factors. Complete closure is key journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 18/09/2025

Multicentre Korean cohort (n=127) assessed switching #IBD pts from IV to SC infliximab. 1-yr treatment persistence was high (92.1%) with no difference between remission & non-remission groups. SC IFX showed stable or improved outcomes & manageable safety journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 18/09/2025

Review on #GIcancer immunotherapy highlights integrated biomarker strategies—from molecular (MSI, TMB, PD-L1), histopathology (CD8+/Treg ratio), to imaging. Combining genetic & imaging data may improve patient selection & treatment monitoring Read here: journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 16/05/2025

In a 240-patient cohort, fecal microbiota transplant for recurrent C. difficile infection failed in 24.6% of cases (18.3% recurrence, 7.1% death within 1 year). Older age, multiple prior episodes, and diabetes were significantly associated with failure. journals.sagepub.com/doi/epdf/10....

010

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 16/05/2025

In the phase IIIb CDI-SCOPE trial, fecal microbiota, live-jslm (REBYOTA®) delivered via colonoscopy prevented CDI recurrence in 95.1% of patients over 8 weeks. Only 9.8% experienced mild, RBL-related TEAEs. Safe, practical, and effective. 🔗 journals.sagepub.com/doi/epdf/10....

011

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 16/05/2025

🩸 A 29-expert Delphi panel reached consensus on 36 statements for managing delayed post-polypectomy bleeding. Key recommendations: risk stratification to reduce unnecessary colonoscopies, and guidance for antithrombotic and hemostatic management 🔗 journals.sagepub.com/doi/epdf/10....

011

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 16/05/2025

🧠 In 1344 non-sedated EGD patients, a pre-procedural anxiety score >36 predicted higher odds of incomplete or poor-quality exams (AUC=0.720). Each 1-point increase in STAI-I raised failure odds by 3.8%. Routine anxiety screening could improve outcomes 🔗 journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 09/05/2025

In unresectable perihilar cholangiocarcinoma, endoscopic therapy goes beyond biliary drainage. ERCP-based approaches + adjuncts like RFA, PDT & EUS methods offer therapeutic promise where surgery isn’t an option. doi.org/10.1177/1756...

011

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 09/05/2025

Smoking, MASLD, cerebrovascular disease, H. pylori persistence, multiple lesions & severe atrophic gastritis all linked to metachronous gastric cancer post-curative ESD. A nomogram showed strong predictive accuracy (C-index up to 0.845). doi.org/10.1177/1756...

001

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 09/05/2025

Anti-reflux mucosectomy significantly improved LES pressure, Hill’s grade, and GERD-related symptom scores vs argon plasma coagulation in Barrett’s esophagus. A stronger reflux barrier with lower lesion residue—supporting ARMS as a dual-target strategy. doi.org/10.1177/1756...

011

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 09/05/2025

In MASLD and MetALD, current smoking significantly worsened survival and increased risks of cirrhosis, CVD, and liver-related mortality. Never smokers had lowest risks across most outcomes. 📊 Supports strong cessation strategies in liver disease care. doi.org/10.1177/1756...

000

Reposted by Therapeutic Advances in Gastroenterology

Jen L, PhD @drjkyl.bsky.social · 02/05/2025

Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings - Apr 24, 2025 @journals.sagepub.com @tagastroenterol.bsky.social journals.sagepub.com/doi/10.1177/... #oncsky #openaccess

032

Reposted by Therapeutic Advances in Gastroenterology

Jen L, PhD @drjkyl.bsky.social · 02/05/2025

Factors associated with failure of fecal microbiota transplant for recurrent Clostridioides difficile infection - Apr 23, 2025 @journals.sagepub.com @tagastroenterol.bsky.social journals.sagepub.com/doi/10.1177/... #gastroenterology #medicine #medsky #openaccess

132

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 16/04/2025

🧠 LLMs show promise for GI research—supporting clinical decisions, data extraction & patient comms—but risks like hallucinations & bias remain. This framework outlines practical steps: goal-setting, fine-tuning, EHR integration & real-world validation 🔗 journals.sagepub.com/doi/epdf/10....

011

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 16/04/2025

🧠 In 104 patients with walled-off necrosis, tailoring LAMS dwell time by imaging & symptoms led to similar success & safety—despite longer stent time (>4wks) in necrosis-heavy cases. Early removal = fewer necrosectomies. Read more: journals.sagepub.com/doi/epdf/10....

121

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 11/04/2025

🚨 For massive rectal GISTs >5cm, transanal endoscopic resection (taLR) matched radical surgery on 5-yr DFS (94.1% vs 100%, p=0.405), while reducing OR time, hospital stay & preserving anal function. A QoL-preserving alternative. Read here: journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 10/04/2025

🆘 In 6 patients with corticosteroid + infliximab-refractory acute severe UC, JAK inhibitors (upadacitinib/tofacitinib) led to clinical response in 4/6 within 72h. All responders were colectomy-free and in steroid-free remission by day 90. Read here: journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 09/04/2025

📊 Despite treatment satisfaction, 29% of Spanish adults with UC still had moderate-to-severe disease, frequent flares, and impaired QoL. Real-world data show clear unmet needs remain—especially for those on biologics or JAK inhibitors Read here: journals.sagepub.com/doi/epdf/10....

110

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 08/04/2025

Switching from IV to SC infliximab was safe in patients with perianal Crohn’s disease: no new lesions over 18 months; 2/3 with active lesions at baseline achieved resolution. Only 1 relapse (2.5%) recaptured remission with SC dose intensification Read: journals.sagepub.com/doi/epdf/10....

100

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 07/04/2025

🇲🇽 Moderate-to-severe IBD activity in Mexico is linked to reduced quality of life, impaired work productivity, and increased healthcare costs—especially in Crohn’s disease. 📊 Data from the RISE-MX trial 🔗 journals.sagepub.com/doi/epdf/10....

100

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 04/04/2025

📊 In Crohn’s disease, adalimumab trough levels at week 6—but not week 2—were linked to biologic remission at weeks 24 & 52, higher 1-year drug survival, and less dose escalation. Week 6 levels >12.27 μg/ml had a PPV of 79.5% for remission at week 24. 🔗 journals.sagepub.com/doi/epdf/10....

100

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 04/04/2025

🔍 A meta-analysis of 8 prospective cohorts (n=12,526) confirms that OLGA and OLGIM stage III–IV significantly increase gastric cancer risk vs stage 0–II (RR 32.3 & 12.4; absolute risk increase 4–5%). Supports use in endoscopic surveillance planning. 🔗 journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 01/04/2025

🔍 In this multicenter cohort study of 130 patients undergoing endoscopic papillectomy, clipping closure of ≥65% of the resection site significantly reduced delayed bleeding (6% vs 25%, p=0.019). Closure rate <65% was an independent risk factor 🔗 journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 01/04/2025

🧫 Gut microbiota dysbiosis plays a key role in colorectal cancer (CRC) pathogenesis. This review explores the therapeutic promise of fecal microbiota transplantation (FMT) to restore balance, modulate immunity, and reshape the tumor microenvironment. 🔗 journals.sagepub.com/doi/epdf/10....

122

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 28/03/2025

📈 Trending this month in Therapeutic Advances in Gastroenterology: Large language models: a primer and gastroenterology applications From clinical practice to education, this review explores how LLMs like ChatGPT are poised to reshape GI. 🔗 journals.sagepub.com/doi/epdf/10....

011

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 27/03/2025

🧠 AI-aided histology in IBD enables precise disease activity scoring, predicts histologic remission, outcomes & treatment response, and standardises pathology in trials. Early work also shows potential in dysplasia detection & barrier healing assessment. journals.sagepub.com/doi/epdf/10....

111

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 26/03/2025

🥣 Real-life data from Dutch patients with mild-to-moderate Crohn’s disease show good adherence and positive experiences with the Crohn’s disease exclusion diet + PEN. Physicians reported sustained effectiveness; patients valued the Modulife platform. 🔗 journals.sagepub.com/doi/epdf/10....

010

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 25/03/2025

📉 In pts with HCV-associated HCC, direct-acting antiviral therapy post-curative treatment suppressed recurrence and improved survival: • 5-year recurrence: 44% (1st), 39% (2nd), 53% (3rd) • 5-year OS: 75% • Fewer prior HCC treatments = better outcomes journals.sagepub.com/doi/epdf/10....

100

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 24/03/2025

⏱️ A multidisciplinary IMID clinic cut diagnostic delays for extraintestinal manifestations (EIMs) in IBD patients by nearly 3 months vs standard referral. It also enabled faster treatment changes and higher use of biologics and immunosuppressants. 🔗 journals.sagepub.com/doi/epdf/10....

010

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 21/03/2025

🔍 ESTD vs ESD for large superficial esophageal lesions: A meta-analysis of 4 RCTs (n=315) shows ESTD significantly reduces operation time and post-op strictures, with similar en bloc and curative resection rates. 📄 journals.sagepub.com/doi/epdf/10....

journals.sagepub.com

Is endoscopic submucosal tunnel dissection better than endoscopic submucosal dissection in treating large superficial esophageal neoplastic lesions? A systematic review and meta-analysis

011

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 20/03/2025

💡 No clear answers on preventing colonic diverticular rebleeding—this systematic review finds no strong evidence supporting lifestyle changes, pharmacological treatments, or endoscopic approaches for prevention. More research is needed. 🔗 Read more: journals.sagepub.com/doi/epdf/10....

100

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 19/03/2025

Baseline tryptophan metabolites may predict remission success in pediatric Crohn’s disease using dietary therapy. This study identifies kynurenine as a key biomarker, offering potential for personalized treatment strategies. 🔗 Read more: journals.sagepub.com/doi/epdf/10....

100

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 18/03/2025

Does the donor's BMI impact body weight changes after fecal microbiota transplantation (FMT) for Clostridioides difficile infection (CDI)? This study found no significant effect, suggesting recipient metabolism plays a larger role. 🔗 Read more: journals.sagepub.com/doi/epdf/10....

100

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 17/03/2025

AI is transforming IBD clinical trials, enhancing recruitment, data analysis, and personalized treatment strategies. This review explores AI’s potential, challenges, and the need for ethical frameworks to ensure inclusivity and accuracy in trial design. 🔗 journals.sagepub.com/doi/epdf/10....

100

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 06/03/2025

This real-world study (n=326) from Mexico examines moderate/severe #IBD cases, highlighting treatment patterns & disease activity. Findings underscore the need for advanced therapies & personalized care to improve outcomes. 🔗 Read: journals.sagepub.com/doi/epdf/10....

110

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 06/03/2025

This study explores how the Crohn’s Disease Therapeutic Diet Intervention influences fatty acid composition & oxidative stress. Findings suggest increased n-3 PUFA intake & reduced pro-inflammatory markers, supporting dietary strategies in #CrohnsDisease 🔗 journals.sagepub.com/doi/epdf/10....

010

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 06/03/2025

Histone deacetylases (HDACs) play a key role in #IBD pathogenesis through epigenetic regulation. This review explores HDAC inhibitors as potential therapeutic targets for ulcerative colitis & #Crohn’s disease and their clinical implications. 🔗 Read: journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 06/03/2025

This study (n=1491) evaluates the learning curve for #endoscopic submucosal dissection (ESD) using a multibending endoscope in early gastric neoplasms. Findings suggest 166 cases are needed to reach proficiency, with strong en bloc & R0 resection rates. 🔗 journals.sagepub.com/doi/epdf/10....

000

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 06/03/2025

This qualitative study (n=18) examines patient perspectives on digital health tools for #IBD self-management. While MyIBDToolkit improved disease monitoring, concerns about usability, privacy, and provider engagement were key barriers. 🔗 Read: journals.sagepub.com/doi/epdf/10....

000